Biohaven's Troriluzole Fails to Meet its Co-Primary Endpoints in P-II/III Study for Alzheimer's Disease
Shots:
- The P-II/III study involves assessing of Troriluzole (qd- PO) vs PBO in 350 patients with mild to mod. AD for up to 48wks.
- The study missed its co-primary endpoints i.e. ADAS-cog & CDR-SB. The therapy also failed to beat PBO on the 2EPs of hippocampal volume assessed by MRI in the overall population
- A subgroup analysis of mild AD patients unveils that troriluzole exhibited a nonsignificant numerical difference of a potential benefit @48wks. on both the ADAS-cog and hippocampal volumetric MRI. Further- secondary & exploratory efficacy analyses and biomarker data including NfL- neurogranin- tau and amyloid are still pending and are expected in the coming mos.
Ref: Biohaven | Image: Biohaven
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com